July 16, 2024 7:44am

Is the 6 positive session trend of the cell and gene therapy sector trend our friend, after dramatic small caps ascension?

As yet another high reaches for how long?

A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today, not tomorrow or yesterday

 

Tuesday: The pre-open Dow futures are DOWN -0.03% or (-11 points), the S&P futures are UP +0.11% or (+6 points) as the Nasdaq futures are UP +0.19% or (+41 points)

  • U.S. stock futures were mixed on Tuesday, 
  • European markets open lower,
  • Asia-Pacific markets were mixed

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday: The Dow closed UP +210.88 points or +0.53%, the S&P closed UP +15.87 points or +0.28% while the Nasdaq closed UP +74.12 points or +0.40%

Economic Data Docket: Retail sales, June (-0.2% expected, +0.1% previously); Import price index, June (-0.1% expected, -0.4% previously); Export price index, June (-0.1% expected, -0.6% previously) and housing market data

 

RegMed Investors (RMi) Closing bell: “RegMed Investors (RMi) Closing Bell: cell and gene therapy sector continues its momentum as many of Friday’s upside few get clipped and some flip. US markets have been particularly volatile in the wake of the attempt on former President Trump's life.” …  https://www.regmedinvestors.com/articles/13539

 

Q3/24:

  • July: 1 market holiday. 1 day off, 2 negative, 1 neutral (previous Friday) and 6 positive closes

Q2/24: 

  • June – 1 market holiday, 7 positive and 1 negative closes
  • May – 1 holiday, 11 positive and 11 negative closes
  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Yet again, I am passing on forecasting the daily indications as I believe many equities have been on a dramatic and upside streak and potentially OVERBOUGHT that COULD be SOLD into by electronic trading focused as the aftermarket fluctuated while the pre-open waits for the all-clear alarm …  it is still a mix of ups, downs and just unknowns.

 

The BOTTOM LINE: For the balance of the month, investors will focus most on share pricing!

Reiterating, “Every time, when I hear and read new highs – I say BYE!”

  • Monday and Friday's rallies sent more sector gains following Thursday's inflation data.

 

The market also continued its rotation into small-cap stocks, with the Russell 2000 rising 1.8% during Monday’s session.

  • Tom Lee, the head of research at Fundstrat Global Advisors, thinks that last week’s big gains for the small-cap index marks just the beginning of a longer rotation. The Russell 2000 posted a 6% gain last week. <CNBC>

 

July week to date: advance/decline lines …

  • (7/15) Monday ended with a positive close of 21 incliners, 9 decliners and 6 flats
  • Friday ended with a positive close of 22 incliners, 11 decliners and 2 flats
  • Thursday ended with a positive close of 31 incliners, 2 decliners and 2 flats
  • Wednesday ended with a positive close of 23 incliners, 10 decliners and 2 flats
  • Tuesday ended with a positive close of 19 incliners, 12 decliners and 4 flats
  • (7/8) Monday ended positive with 24 incliners, 8 decliners and 3 flats
  • Friday ended with a neutral close of 16 incliners, 16 decliners and 3 flats
  • Thursday was a market holiday
  • Wednesday was a day off
  • Tuesday ended with a negative close of 6 incliners, 19 decliners and 3 flats
  • (7/1) Monday ended with a negative close of 13 incliners, 19 decliners and 3 flats

 

Are we headed to a clash of algos and electronic trading regarding share pricing?

 

Due “dates” are DUE soon for Q2 LPS (loss per-share) boding releases:

  • I’m still NOT feeling optimism --- it’s only a party for visits from “uncle algo and his electronic trading dwarfs”!
  • Reiterating, “There is still the issue of the lack of catalysts as we head into Q2 earnings season.”

 

Watch the “numbers, charts and indicators” measure the daily, weekly, and monthly charts can filter out or lessen the noise of back-and-forth share pricing from sector rotation.

  • The short-term moving averages help you identify the momentum of the trend — that is, overbought or oversold

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.